BHARAT PARENTERALS Latest Share Price (BPLPHARMA)
TODAY IN ONE LINE
BPLPHARMA jumped 3.5%, outperforming Nifty's 2.0% move, supported by recent strong earnings.
With a market cap of ₹1,277.56 Cr., it trades at a P/E of 1029.83. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
BHARAT PARENTERALS flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 45.4% and Profit up 431.7%
- ●High Promoter HoldingPromoters hold 67.2% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest BHARAT PARENTERALS News
What changed recently?
Recent events, corporate actions, and announcements.
BHARAT PARENTERALS valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for BHARAT PARENTERALS, framed against the sector median so the premium or discount is obvious at a glance.
BHARAT PARENTERALS trades at a P/E of 1029.83× and P/B of 3.85×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
BHARAT PARENTERALS technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for BHARAT PARENTERALS — derived from the latest tape, not yesterday's close.
BHARAT PARENTERALS last traded at ₹1,881.9 with an intraday range of ₹1,793.1–₹1,982.8 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1881.90| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2358.17 | +476.27 | +25.31% |
| R3 | 2168.47 | +286.57 | +15.23% |
| R2 | 2075.63 | +193.73 | +10.29% |
| R1 | 1978.77 | +96.87 | +5.15% |
| PIVOT | 1885.93 | 4.03 | 0.21% |
| CURRENT | 1881.90 | — | — |
| S1 | 1789.07 | -92.83 | -4.93% |
| S2 | 1696.23 | -185.67 | -9.87% |
| S3 | 1599.37 | -282.53 | -15.01% |
| S4 | 1409.67 | -472.23 | -25.09% |
BPLPHARMA is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹1850–₹1982.8
Trading Above opening range, showing Bullishness
BHARAT PARENTERALS financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for BHARAT PARENTERALS — consolidated or standalone — with margins, YoY growth and key ratios inline.
BHARAT PARENTERALS reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1,277.56 Cr. and reported EPS of ₹13.66.
| Metric | Mar 2026 | May 2026 |
|---|---|---|
| Revenue from Operations | 345 | 345 ▲ 0.0% |
| Sales Growth YoY %Derived | 1.48% | 1.48% |
| Other Income | 10 | 10 ▲ 0.0% |
| Total Income | 355 | 355 ▲ 0.0% |
| 191 | 191 ▲ 0.0% | |
| Gross ProfitDerived | 154 | 154 ▲ 0.0% |
| Gross Margin %Derived | 44.59% | 44.59% |
| 138 | 138 ▲ 0.0% | |
| EBITDA (Operating Profit)Derived | 16 | 16 ▲ 0.0% |
| OPM %Derived | 4.58% | 4.58% |
| 47 | 47 ▲ 0.0% | |
| Profit Before Tax (PBT) | -21 | -21 ▲ 0.0% |
| 6 | 6 ▲ 0.0% | |
| Effective Tax %Derived | -27.46% | -27.46% |
| Total Profit for Period | -27 | -27 ▲ 0.0% |
| Less: Non-controlling Interests | -19 | -19 ▲ 0.0% |
| Net Profit (Owner's PAT)Derived | -8 | -8 ▲ 0.0% |
| Net Profit Margin %Derived | -2.37% | -2.37% |
| PAT Growth YoY %Derived | 81.26% | 81.26% |
| Earnings Per Share (EPS ₹) | -11.88 | -11.88 ▲ 0.0% |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 1 | 1 ▲ 0.0% |
| Total Expenses (incl. D&A & Interest) | 376 | 376 ▲ 0.0% |
| Material Cost % of RevenueDerived | 49.00% | 49.00% |
| Employee Cost % of RevenueDerived | 19.48% | 19.48% |
| Other Cost % of RevenueDerived | 20.54% | 20.54% |
| Interest Coverage (x)Derived | -1.47x | -1.47x |
| Period | Mar 2019 | May 2019 | Mar 2020 | Jun 2020 | Mar 2021 | Jun 2021 | Mar 2022 | Jun 2022 | Mar 2023 | Jun 2023 | Mar 2024 | Jul 2024 | Mar 2025 | May 2025 | Mar 2026 | May 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 220 | 220 ▲ 0.0% | 228 ▲ 3.9% | 228 ▲ 0.0% | 205 ▼ 10.3% | 205 ▲ 0.0% | 212 ▲ 3.6% | 212 ▲ 0.0% | 218 ▲ 2.8% | 218 ▲ 0.0% | 257 ▲ 18.1% | 257 ▲ 0.0% | 340 ▲ 32.3% | 340 ▲ 0.0% | 345 ▲ 1.5% | 345 ▲ 0.0% | |
| Sales Growth YoY %Derived | — | — | 3.94% | — | -10.32% | -10.32% | 3.60% | 3.60% | 2.82% | 2.82% | 18.07% | — | 32.26% | — | 1.48% | 1.48% | |
| Other Income | 13 | 13 ▲ 0.0% | 11 ▼ 9.6% | 11 ▲ 0.0% | 9 ▼ 24.4% | 9 ▲ 0.0% | 8 ▼ 10.4% | 8 ▲ 0.0% | 12 ▲ 50.9% | 12 ▲ 0.0% | 9 ▼ 26.8% | 9 ▲ 0.0% | 12 ▲ 38.5% | 12 ▼ 2.4% | 10 ▼ 17.9% | 10 ▲ 0.0% | |
| Total Income | 232 | 232 ▲ 0.0% | 240 ▲ 3.2% | 240 ▲ 0.0% | 213 ▼ 11.0% | 213 ▲ 0.0% | 220 ▲ 3.0% | 220 ▲ 0.0% | 230 ▲ 4.5% | 230 ▲ 0.0% | 266 ▲ 15.8% | 266 ▲ 0.0% | 352 ▲ 32.5% | 352 ▼ 0.1% | 355 ▲ 0.8% | 355 ▲ 0.0% | |
140 | 140 ▲ 0.0% | 149 ▲ 6.0% | 149 ▲ 0.0% | 134 ▼ 9.8% | 134 ▲ 0.0% | 136 ▲ 1.3% | 136 ▲ 0.0% | 137 ▲ 1.0% | 137 ▲ 0.0% | 158 ▲ 15.2% | 158 ▲ 0.0% | 185 ▲ 17.1% | 185 ▲ 0.0% | 191 ▲ 3.2% | 191 ▲ 0.0% | ||
| Gross ProfitDerived | 79 | 79 ▲ 0.0% | 79 ▲ 0.3% | 79 ▲ 0.0% | 70 ▼ 11.2% | 70 ▲ 0.0% | 76 ▲ 7.9% | 76 ▲ 0.0% | 81 ▲ 6.0% | 81 ▲ 0.0% | 99 ▲ 23.0% | 99 ▲ 0.0% | 155 ▲ 56.5% | 155 ▲ 0.0% | 154 ▼ 0.6% | 154 ▲ 0.0% | |
| Gross Margin %Derived | 36.01% | 36.01% | 34.74% | 34.74% | 34.39% | 34.39% | 35.82% | 35.82% | 36.93% | 36.93% | 38.47% | 38.47% | 45.51% | 45.51% | 44.59% | 44.59% | |
50 | 50 ▲ 0.0% | 51 ▲ 2.0% | 51 ▲ 0.0% | 45 ▼ 11.8% | 45 ▲ 0.0% | 48 ▲ 7.0% | 48 ▲ 0.0% | 61 ▲ 25.5% | 61 ▲ 0.0% | 77 ▲ 26.4% | 77 ▲ 0.0% | 152 ▲ 98.6% | 152 ▲ 0.0% | 138 ▼ 9.2% | 138 ▲ 0.0% | ||
| EBITDA (Operating Profit)Derived | 29 | 29 ▲ 0.0% | 28 ▼ 2.8% | 28 ▲ 0.0% | 25 ▼ 10.1% | 25 ▲ 0.0% | 28 ▲ 9.5% | 28 ▲ 0.0% | 20 ▼ 28.1% | 20 ▲ 0.0% | 22 ▲ 12.5% | 22 ▲ 0.0% | 3 ▼ 87.9% | 3 ▲ 0.0% | 16 ▲ 485.8% | 16 ▲ 0.0% | |
| OPM %Derived | 13.16% | 13.16% | 12.30% | 12.30% | 12.33% | 12.33% | 13.04% | 13.04% | 9.12% | 9.12% | 8.69% | 8.69% | 0.79% | 0.79% | 4.58% | 4.58% | |
7 | 7 ▲ 0.0% | 7 ▼ 3.7% | 7 ▲ 0.0% | 7 ▲ 0.9% | 7 ▲ 0.0% | 8 ▲ 11.0% | 8 ▲ 0.0% | 8 ▲ 6.9% | 8 ▲ 0.0% | 12 ▲ 51.7% | 12 ▲ 0.0% | 49 ▲ 296.7% | 48 ▼ 0.6% | 47 ▼ 3.1% | 47 ▲ 0.0% | ||
| Profit Before Tax (PBT) | 35 | 35 ▲ 0.0% | 33 ▼ 5.2% | 33 ▲ 0.0% | 27 ▼ 17.3% | 27 ▲ 0.0% | 28 ▲ 2.8% | 28 ▲ 0.0% | 24 ▼ 15.5% | 24 ▲ 0.0% | 19 ▼ 20.5% | 19 ▲ 0.0% | -34 ▼ 281.4% | -34 ▲ 0.0% | -21 ▲ 36.9% | -21 ▲ 0.0% | |
13 | 13 ▲ 0.0% | 9 ▼ 35.2% | 9 ▲ 0.0% | 7 ▼ 21.3% | 7 ▲ 0.0% | 7 ▲ 3.8% | 7 ▲ 0.0% | 8 ▲ 10.7% | 8 ▲ 0.0% | 8 ▲ 5.1% | 8 ▲ 0.0% | 9 ▲ 12.0% | 9 ▲ 0.0% | 6 ▼ 36.2% | 6 ▲ 0.0% | ||
| Effective Tax %Derived | 38.58% | 38.58% | 26.36% | 26.36% | 25.11% | 25.11% | 25.36% | 25.36% | 33.25% | 33.25% | 43.96% | 43.96% | -27.16% | -27.16% | -27.46% | -27.46% | |
| Total Profit for Period | 21 | 21 ▲ 0.0% | 24 ▲ 13.7% | 24 ▲ 0.0% | 20 ▼ 15.9% | 20 ▲ 0.0% | 21 ▲ 2.5% | 21 ▲ 0.0% | 16 ▼ 24.5% | 16 ▲ 0.0% | 11 ▼ 33.1% | 11 ▲ 0.0% | -44 ▼ 515.2% | -44 ▲ 0.0% | -27 ▲ 37.5% | -27 ▲ 0.0% | |
| Less: Non-controlling Interests | — | — | — | — | -0 | -0 ▲ 0.0% | -0 ▼ 242.9% | -0 ▲ 0.0% | -1 ▼ 183.3% | -1 ▲ 0.0% | — ▲ 100.0% | — | — | — | -19 | -19 ▲ 0.0% | |
| Net Profit (Owner's PAT)Derived | 21 | 21 ▲ 0.0% | 24 ▲ 13.7% | 24 ▲ 0.0% | 20 ▼ 15.6% | 20 ▲ 0.0% | 21 ▲ 3.3% | 21 ▲ 0.0% | 16 ▼ 22.1% | 16 ▲ 0.0% | 11 ▼ 35.9% | 11 ▲ 0.0% | -44 ▼ 515.2% | -44 ▲ 0.0% | -8 ▲ 81.3% | -8 ▲ 0.0% | |
| Net Profit Margin %Derived | 9.68% | 9.68% | 10.59% | 10.59% | 9.96% | 9.96% | 9.93% | 9.93% | 7.52% | 7.52% | 4.09% | 4.09% | -12.83% | -12.83% | -2.37% | -2.37% | |
| PAT Growth YoY %Derived | — | — | 13.71% | — | -15.65% | -15.65% | 3.29% | 3.29% | -22.09% | -22.09% | -35.85% | — | -515.21% | — | 81.26% | 81.26% | |
| Earnings Per Share (EPS ₹) | 37.08 | 37.08 ▲ 0.0% | 42.17 ▲ 13.7% | 42.17 ▲ 0.0% | 35.59 ▼ 15.6% | 35.59 ▲ 0.0% | 36.45 ▲ 2.4% | 36.45 ▲ 0.0% | 28.47 ▼ 21.9% | 28.47 ▲ 0.0% | 18.08 ▼ 36.5% | 18.08 ▲ 0.0% | -63.38 ▼ 450.6% | -63.38 ▲ 0.0% | -11.88 ▲ 81.3% | -11.88 ▲ 0.0% | |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.8% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.8% | 1 ▲ 0.0% | 1 ▲ 18.4% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -0 | -0 ▲ 0.0% | 0 ▲ 145.5% | 0 ▲ 0.0% | 0 ▲ 300.0% | 0 ▲ 0.0% | -0 ▼ 243.8% | -0 ▲ 0.0% | 0 ▲ 117.4% | 0 ▲ 0.0% | -0 ▼ 600.0% | -0 ▲ 0.0% | 0 ▲ 200.0% | 0 ▲ 0.0% | 1 ▲ 188.6% | 1 ▲ 0.0% | |
| Total Expenses (incl. D&A & Interest) | 198 | 198 ▲ 0.0% | 207 ▲ 4.7% | 207 ▲ 0.0% | 186 ▼ 10.0% | 186 ▲ 0.0% | 192 ▲ 3.1% | 192 ▲ 0.0% | 206 ▲ 7.4% | 206 ▲ 0.0% | 247 ▲ 19.9% | 247 ▲ 0.0% | 386 ▲ 56.2% | 386 ▼ 0.1% | 376 ▼ 2.5% | 376 ▲ 0.0% | |
| Material Cost % of RevenueDerived | 43.71% | 43.71% | 57.29% | 57.29% | 62.12% | 62.12% | 62.60% | 62.60% | 67.01% | 67.01% | 67.28% | 67.28% | 52.34% | 52.34% | 49.00% | 49.00% | |
| Employee Cost % of RevenueDerived | 7.00% | 7.00% | 6.83% | 6.83% | 7.21% | 7.21% | 7.25% | 7.25% | 8.26% | 8.26% | 8.85% | 8.85% | 14.59% | 14.59% | 19.48% | 19.48% | |
| Other Cost % of RevenueDerived | 15.86% | 15.86% | 15.61% | 15.61% | 14.85% | 14.85% | 15.53% | 15.53% | 19.55% | 19.55% | 20.92% | 20.92% | 30.13% | 30.13% | 20.54% | 20.54% | |
| Interest Coverage (x)Derived | 26.16x | 26.16x | 25.80x | 25.80x | 24.95x | 24.95x | 23.58x | 23.58x | 6.39x | 6.39x | 4.15x | 4.15x | -2.47x | -2.52x | -1.47x | -1.47x |
BHARAT PARENTERALS segment analysis : revenue and profit mix.
Disclosed business segments at BHARAT PARENTERALS with their share of revenue and profit, switchable between consolidated and standalone reporting.
BHARAT PARENTERALS discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for BHARAT PARENTERALS.
Our AI distills the core fundamental drivers supporting BHARAT PARENTERALS, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Valuation risk. a P/E above 1339 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Income thesis breaks if the dividend is cut or yield falls below 0.03%.
BHARAT PARENTERALS peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — BHARAT PARENTERALS is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
BHARAT PARENTERALS chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for BHARAT PARENTERALS — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
BHARAT PARENTERALS delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for BHARAT PARENTERALS over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in BHARAT PARENTERALS stood at 38.8% of traded volume, against a 20-day average of 48.2%.
BHARAT PARENTERALS announcements: results, concalls, ratings, M&A.
Filings BHARAT PARENTERALS sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
BHARAT PARENTERALS files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 77 documents below.
Board Meeting
Outcome of the board meeting for the board approves the Preferential Allotment
Insider Trading / SAST
Intimation for the closure of the trading Window in terms of the SEBI (Prohibition of Insider Trading) Regulations, 2015
Board Meeting
Bharat Parenterals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/09/2026 ,inter alia, to consider…
AGM/EGM
Voting Results along with the scrutinizer report for the 33rd AGM held on Saturday, September 19, 2026.
AGM/EGM
Intimation of Proceedings of the 33rd Annual General Meeting of the Company held on September 19, 2026.
Investor decks & rating reports.
BHARAT PARENTERALS dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue BHARAT PARENTERALS has declared, sequenced by announce and record date.
BHARAT PARENTERALS corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About BHARAT PARENTERALS: business, sector, key facts.
What BHARAT PARENTERALS does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
BHARAT PARENTERALS is a listed Indian equity.
BHARAT PARENTERALS
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B BLACKBIO DX (3BBLACKBIO) Share PricePeer
- ABBOTT INDIA (ABBOTINDIA) Share PricePeer
- ACUTAAS CHEMICALS (ACUTAAS) Share PricePeer
- ANLON HEALTHCARE (AHCL) Share PricePeer
- AMANTA HEALTHCARE (AMANTA) Share PricePeer
- Top Gainers TodayScreener
- Other overvalued NSE stocksScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about BHARAT PARENTERALS (BPLPHARMA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of BHARAT PARENTERALS (BPLPHARMA)?
The current share price of BHARAT PARENTERALS (BPLPHARMA) is ₹1,881.90. Today, the stock has gained by ₹62.90 (3.46%), trading in a range of ₹1,793.10 to ₹1,982.80. The stock opened at ₹1,850.00 with a trading volume of 5,812 shares.
02Is BHARAT PARENTERALS stock a good investment for long-term?
BHARAT PARENTERALS can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,277.56 Cr., P/E ratio of 1,029.83, ROE of 0%, and ROCE of 0%. The dividend yield stands at 0.05%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of BHARAT PARENTERALS stock?
The 52-week high price of BHARAT PARENTERALS (BPLPHARMA) is ₹2,295.10, while the 52-week low is ₹1,125.70. Currently trading at ₹1,881.90, the stock is 67.18% above its 52-week low and 18% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy BHARAT PARENTERALS stock at the current price?
Whether to buy BHARAT PARENTERALS stock at ₹1,881.90 depends on multiple factors. The stock is currently trading with a P/E ratio of 1,029.83 and P/B ratio of 3.85. Today's performance shows a gain of 3.46%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of BHARAT PARENTERALS and when is the next dividend?
BHARAT PARENTERALS offers a dividend yield of 0.05%, which means for every ₹100 invested at the current price of ₹1,881.90, you can expect to receive approximately ₹0.05 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06How is BHARAT PARENTERALS stock performing today in the market?
BHARAT PARENTERALS stock opened at ₹1,850.00 and is currently trading at ₹1,881.90, showing a gain of ₹62.90 (3.46%). The intraday high is ₹1,982.80 and low is ₹1,793.10. The trading volume stands at 5,812 shares, indicating moderate market participation today.
07What is the P/E ratio of BHARAT PARENTERALS and what does it indicate?
BHARAT PARENTERALS has a Price-to-Earnings (P/E) ratio of 1,029.83, which means investors are willing to pay 1,029.83 for every ₹1 of earnings. With an EPS of ₹13.66, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
08What is the market capitalization of BHARAT PARENTERALS?
BHARAT PARENTERALS has a market capitalization of ₹1,277.56 Cr., making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹1,881.90) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
The data, ratios and commentary about BHARAT PARENTERALS (BPLPHARMA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.